Futu Information on July 6 | all three major indices fell, with the Hang Seng Index falling 1.37%, the Hang Seng Technology Index down 1.13% and the National Index down 1.51%.

By midday's close, Hong Kong stocks were up 521, down 1154, and closed flat at 1202.

The specific industry performance is shown below:

In the sector, most of the large technology stocks fell.BABA rose more than 1%, Tencent fell 0.86%, JD.com fell 4%, and Meituan fell more than 1%.

Education stocks strengthenNew Oriental Education & Technology Group-S rose by more than 11%, New Oriental Education & Technology Group online by more than 6%, and Tianli International by more than 5%.

Pharmaceutical stocks continue to riseKangfang Bio-B rose by more than 8%, Tigermed by more than 4%, and BeiGene, Ltd. by more than 12%.

Green Power concept stocks are among the top gainers.China's electricity rose by more than 6%, China Resources Power Holdings by more than 3% and China Longyuan Power Group Corporation by more than 4%.

Auto stocks fell.Byd Company Limited fell 0.38%, Geely Automobile and Great Wall Motor fell more than 2%.

Oil stocks fell.CNOOC Limited fell more than 5 per cent, Petrochina fell more than 4 per cent and China Oilfield Services fell more than 6 per cent.

Coal stocks plummetedChina Shenhua Energy fell more than 5 per cent, Yanzhou Mining Energy fell more than 9 per cent and China Coal Energy fell 7 per cent.

Individual stocks$BABA-SW (09988.HK) $It's up more than 1%.BABA's share price rose more than 16% in June and was favored by many institutions. Xiaomo raised BABA's target price by 7.6% to HK $135, maintaining its "overweight" rating, while Daiwa raised BABA's target price by 3% to HK $150 to maintain its "buy" rating. Macquarie raised BABA's target price by 5% to HK $145, maintaining its "outperform" rating.

$New Oriental Education & Technology Group-S (09901.HK) $It rose by more than 11%.According to new data, Oriental selection studio sales reached 681 million yuan throughout June, ranking first in Douyin live streaming.

China Electric Power (02380.HK) $It's up more than 6%.On the news side, the China Federation of Electric Power Enterprises said that considering the international situation, epidemic prevention and control, fuel supply and other factors, the overall balance of national power supply and demand in 2022, during the peak summer and winter, power supply in some areas is tight, and the electricity consumption of the whole society is expected to grow by 5% and 6% in 2022.

$Kangfang Bio-B (09926.HK) $It's up more than 8%.Kang Fang biological independent research and development of PD-1/CTLA-4 bispecific antibody new drug Caduniril monoclonal antibody has been officially approved on the market, the agency pointed out that the double antibody technology has been recognized by the market, the company's commercial team is ready to start, it is expected that the product will achieve rapid volume after commercialization.

$BeiGene, Ltd. (06160.HK) $It rose by more than 12%.Recently, BeiGene, Ltd. released the data of the phase 3 global clinical trial of tirelizumab developed by BeiGene, Ltd.. The data showed that tirelizumab combined with chemotherapy broke the longest survival record in the treatment of first-line advanced or metastatic esophageal squamous cell carcinoma, with a median overall survival time (mOS) of 17.2 months. Everbright Securities pointed out that biotechnology is expected to become a track with both valuation advantages and high prosperity.

$Yanzhou Mining Energy (01171.HK) $Down more than 9%.In the news, Zhang Hong, spokesman for the China Coal Industry Association, said that with the arrival of the peak period of coal consumption in summer, the demand for coal has gradually rebounded, but at the same time hydropower and new energy power generation continue to maintain rapid growth, and the role of coal substitution is also increasing.

Half-day turnover TOP20